A class of medications known as the atypical antipsychotics. both conventional antipsychotics and atypical antipsychotics are antagonists of dopamine receptors; however, the newer agents are also potent antagonists of serotonin receptors (5-HT2A). As a result of this distinctive receptor profile, SDAs may be more effective than conventional antipsychotics in reducing negative symptoms of schizophrenia. they also may produce fewer extrapyramidal symptoms (EPS) and decrease the risk for developing tardive dyskinesia with long-term use; however, SDAs and conventional antipsychotics are equally effective in treating the positive symptoms of schizophrenia.